SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Omega Fund Management, LLC

CIK 0001637359 · 888 BOYLSTON ST., SUITE 1111, BOSTON, MA, 02199 · 617 502 6538

Reported Value
$1.5B
Q3 2021
Positions
30
includes revealed positions
Filings on Record
34
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Omega Fund Management, LLC reported $1.5B in U.S.-listed holdings across 30 positions for Q3 2021.

The portfolio is heavily concentrated: NUVB alone accounts for 56.1% of reported value.

Compared with Q2 2021, the fund opened 5 new positions and exited 0.

Portfolio Metrics

Turnover
+13.1%
vs prior filed quarter
Top-10 Concentration
+92.4%
share of reported value
Largest Position
+56.1%
Nuvation Bio

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $135MQ4 ’18Q1 ’19: $473MQ2 ’19: $392MQ3 ’19: $324MQ4 ’19: $314MQ4 ’19Q1 ’20: $242MQ2 ’20: $366MQ3 ’20: $370MQ4 ’20: $667MQ4 ’20Q1 ’21: $734MQ2 ’21: $604MQ3 ’21: $1.5BQ4 ’21: $707MQ4 ’21Q1 ’22: $489MQ2 ’22: $313MQ3 ’22: $273MQ4 ’22: $297MQ4 ’22Q1 ’23: $153MQ2 ’23: $178MQ3 ’23: $109MQ4 ’23: $123MQ4 ’23Q1 ’24: $155MQ2 ’24: $135MQ3 ’24: $160MQ4 ’24: $121MQ4 ’24Q1 ’25: $169MQ2 ’25: $154MQ3 ’25: $222MQ4 ’25: $287MQ4 ’25Q1 ’26: $163Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 91.0%Other: 8.9%ADR: 0.1%
  • Common Stock · 91.0% · $1.4B
  • Other · 8.9% · $132M
  • ADR · 0.1% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NUVBNuvation BioREVEALEDNEW+84.64M84.64M+$838M$838M
SANASana Biotechnology, Inc.REVEALEDNEW+2.53M2.53M+$64M$64M
Imago BiosciencesNEW+3.02M3.02M+$60M$60M
IVVDAdagio TherapeuticsNEW+632.9K632.9K+$27M$27M
IcosavaxNEW+426.4K426.4K+$13M$13M
AVIRAtea PharmaceuticalsTRIMMED−582.3K164.6K−$10M$6M
NVLSEURAlpine Immune SciencesADDED+744.7K2.03M+$10M$22M
MORFUSDMorphic HoldingTRIMMED−451.4K1.32M−$27M$75M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021REVEALED

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NUVBNuvation BioREVEALEDhistory →Common Stock56.10%$838M84.64M
2REPLReplimune Grouphistory →Common Stock9.72%$145M4.90M
3KRON1USDKronos Biohistory →Common Stock5.36%$80M3.82M
4MORFUSDMorphic Holdinghistory →Common Stock4.99%$75M1.32M
5SANASana Biotechnology, Inc.REVEALEDhistory →Common Stock4.27%$64M2.53M
6Imago BiosciencesCommon Stock4.05%$60M3.02M
7GOSSGossamer Biohistory →Common Stock2.79%$42M3.32M
8Ikena OncologyCommon Stock1.90%$28M2.25M
9IVVDAdagio Therapeuticshistory →Common Stock1.79%$27M632.9K
10NVLSEURAlpine Immune Scienceshistory →Common Stock1.45%$22M2.03M
11VTLUSDImmunic Inchistory →Common Stock1.06%$16M1.79M
12ARQTArcutis Biothereapeuticshistory →Common Stock1.00%$15M623.8K
13Spruce BiosciencesCommon Stock0.87%$13M2.16M
14PRTKEURParatek Pharmaceuticalshistory →Common Stock0.85%$13M2.61M
15IcosavaxCommon Stock0.84%$13M426.4K
16SYRSEURSyros Pharmaceuticalshistory →Common Stock0.75%$11M2.51M
17AVIRAtea PharmaceuticalsCommon Stock0.39%$6M164.6K
18Checkmate PharmaceuticalsCommon Stock0.35%$5M1.34M
19Omega Alpha SPACCommon Stock0.33%$5M501.0K
20Cidara TherapeuticsCommon Stock0.30%$4M2.01M
21ObsEva SACommon Stock0.21%$3M999.4K
22EPIEURESSA PharmaCommon Stock0.18%$3M328.2K
23JNCEEURJounce TherapeuticsCommon Stock0.14%$2M275.5K
24IMCRImmunocore HoldingsCommon Stock0.13%$2M51.5K
25TRVITrevi TherapeuticsCommon Stock0.12%$2M1.26M
26FGENEURFibroGen IncCommon Stock0.08%$1M130.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$163M10May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$287M11Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$222M12Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$154M13Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$169M13May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$121M11Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$160M11Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$135M11Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$155M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$123M14Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$109M12Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$178M12Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$153M14May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$297M16Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M19Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$313M21Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$489M22May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$707M22Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021REVEALED$1.5B30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$604M21Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$734M22May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$667M19Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$370M16Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$366M15Aug 17, 202013F-HRchanges · EDGAR ↗
Q1 2020$242M16May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$314M14Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$324M14Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$392M15Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019REVEALED$473M25May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$135M14Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.